Erasca, Inc.
ERAS
株式のランク
#3402
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
株価
$14.62
最終同期: 2026-10-20
時価総額
$5.11B
変化（1日）
7.34%
変化（1年）
514.29%
国
US
取引 Erasca, Inc. (ERAS)
カテゴリー
Healthcare
Erasca, Inc.（ERAS）のP/B比率
October 2026 時点のP/B比率 TTM: 12.65
Erasca, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 12.65 です。2023 年末時点でのP/B比率は 1.01 でした。
Erasca, Inc. の P/B 比率の履歴（2019 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 12.65 | 809.88% |
| 2024 | 1.39 | 37.19% |
| 2023 | 1.01 | -20.90% |
| 2022 | 1.28 | -68.58% |
| 2021 | 4.06 | -122.34% |
| 2020 | -18.19 | -88.07% |
| 2019 | -152.41 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -50.57% |
US
|
|
| 13.2547 | 4.80% |
US
|
|
| 4.208 | -66.73% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -51.12% |
NL
|
